» Articles » PMID: 34513293

HMEJ-mediated Site-specific Integration of a Myostatin Inhibitor Increases Skeletal Muscle Mass in Porcine

Overview
Publisher Cell Press
Date 2021 Sep 13
PMID 34513293
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

As a robust antagonist of myostatin (), follistatin () is an important regulator of skeletal muscle development, and the delivery of to muscle tissue represents a potential therapeutic strategy for muscular dystrophies. The N terminus and FSI domain of are the functional domains for binding. Here, we aimed to achieve site-specific integration of FSI-I-I, including the signal peptide, N terminus, and three FSI domains, into the last codon of the porcine gene using a homology-mediated end joining (HMEJ)-based strategy mediated by CRISPR-Cas9. Based on somatic cell nuclear transfer (SCNT) technology, we successfully obtained FSI-I-I knockin pigs. H&E staining of longissimus dorsi and gastrocnemius cross-sections showed larger myofiber sizes in FSI-I-I knockin pigs than in controls. Moreover, the Smad and Erk pathways were inhibited, whereas the PI3k/Akt pathway was activated in FSI-I-I knockin pigs. In addition, the levels of , , and transcription were upregulated while that of was downregulated in FSI-I-I knockin pigs. These results indicate that the FSI-I-I gene mediates skeletal muscle hypertrophy through an -related signaling pathway and the expression of myogenic regulatory factors. Overall, FSI-I-I knockin pigs with hypertrophic muscle tissue hold great promise as a therapeutic model for human muscular dystrophies.

Citing Articles

CRISPR Technology Acts as a Dual-Purpose Tool in Pig Breeding: Enhancing Both Agricultural Productivity and Biomedical Applications.

Fu B, Ma H, Huo X, Zhu Y, Liu D Biomolecules. 2024; 14(11).

PMID: 39595585 PMC: 11591810. DOI: 10.3390/biom14111409.


Loss of MuRF1 in Duroc pigs promotes skeletal muscle hypertrophy.

Li J, Hu Y, Li J, Wang H, Wu H, Zhao C Transgenic Res. 2023; 32(3):153-167.

PMID: 37071377 DOI: 10.1007/s11248-023-00342-0.


Correction of intron 1 inversion in hemophilia A patient-specific iPSCs by CRISPR/Cas9 mediated gene editing.

Hu Z, Wu Y, Xiao R, Zhao J, Chen Y, Wu L Front Genet. 2023; 14:1115831.

PMID: 36968612 PMC: 10033665. DOI: 10.3389/fgene.2023.1115831.


Enhancing Animal Disease Resistance, Production Efficiency, and Welfare through Precise Genome Editing.

Liu Z, Wu T, Xiang G, Wang H, Wang B, Feng Z Int J Mol Sci. 2022; 23(13).

PMID: 35806334 PMC: 9266401. DOI: 10.3390/ijms23137331.


TERT Promoter Revertant Mutation Inhibits Melanoma Growth through Intrinsic Apoptosis.

Wang Y, Chen Y, Li C, Xiao Z, Yuan H, Zhang Y Biology (Basel). 2022; 11(1).

PMID: 35053139 PMC: 8773187. DOI: 10.3390/biology11010141.

References
1.
Ueno N, Ling N, Ying S, Esch F, Shimasaki S, Guillemin R . Isolation and partial characterization of follistatin: a single-chain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone. Proc Natl Acad Sci U S A. 1987; 84(23):8282-6. PMC: 299526. DOI: 10.1073/pnas.84.23.8282. View

2.
Moretti I, Ciciliot S, Dyar K, Abraham R, Murgia M, Agatea L . MRF4 negatively regulates adult skeletal muscle growth by repressing MEF2 activity. Nat Commun. 2016; 7:12397. PMC: 4976255. DOI: 10.1038/ncomms12397. View

3.
Qi L, Larson M, Gilbert L, Doudna J, Weissman J, Arkin A . Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013; 152(5):1173-83. PMC: 3664290. DOI: 10.1016/j.cell.2013.02.022. View

4.
Mayer K, Buchbinder A, Morty R . Activin A: a mediator governing inflammation, immunity, and repair. Am J Respir Crit Care Med. 2012; 185(4):350-2. DOI: 10.1164/rccm.201112-2210ED. View

5.
Srivastava M, Nambiar M, Sharma S, Karki S, Goldsmith G, Hegde M . An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression. Cell. 2012; 151(7):1474-87. DOI: 10.1016/j.cell.2012.11.054. View